Company Filing History:
Years Active: 2010
Title: The Innovative Contributions of Søren Jepsen
Introduction
Søren Jepsen is a notable inventor based in Holte, Denmark. He has made significant strides in the field of medical research, particularly in the development of vaccines. His work has the potential to impact global health, especially in combating malaria.
Latest Patents
Søren Jepsen holds a patent for a malaria vaccine. This innovative vaccine is a fusion protein derived from Glutamate-rich protein (GLURP) genetically coupled to Merozoite surface protein 3 (MSP3). The recombinant GLURP-MSP3 hybrid protein was produced as a secreted entity, and experiments demonstrated that the GLURP component enhances the overall antibody response. Immunizations with this hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains compared to other methods of administration. The findings suggest that T cell epitopes in the GLURP region provide essential help for B-cell epitopes in the MSP3 region. Furthermore, the hybrid protein was shown to be more antigenic than the individual recombinant proteins, indicating its potential as a protective antigen.
Career Highlights
Søren Jepsen is affiliated with Statens Serum Institut, where he continues to contribute to vaccine research and development. His work has garnered attention for its innovative approach to enhancing immune responses against malaria.
Collaborations
One of his notable collaborators is Michael Theisen, with whom he has worked on various research projects related to vaccine development.
Conclusion
Søren Jepsen's contributions to the field of vaccine research, particularly with his malaria vaccine, highlight the importance of innovation in addressing global health challenges. His work exemplifies the potential of scientific research to create impactful solutions.